BBI 825
Alternative Names: BBI-825Latest Information Update: 08 Apr 2024
At a glance
- Originator Boundless Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Ribonucleotide reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 28 Mar 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT06299761)
- 08 Mar 2024 Boundless Bio plans a phase I STARMAP trial in Solid tumour (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT06299761)
- 13 Oct 2023 Pharmacodynamics data from a preclinical trial in Cancer released by Boundless Bio